INTRODUCTION
Two classes of drugs, inhibitors of BRAF signaling (Flaherty et al., 2010) and checkpoint inhibitors Allison, 2015a and 2015b) , have recently achieved substantial survival advantages in melanoma patients. Despite initial high clinical responses to BRAF blockade in BRAF V600E -mutated melanoma patients, most tumor lesions relapse within a few months after therapy initiation (Flaherty et al., 2010) . BRAF inhibition can induce tumor cell death and the release of tumor antigens and therefore represents a unique opportunity to increase T cell immunity against readily available tumor-associated antigens (Kroemer et al., 2013) . Three checkpoint inhibitors have been actively explored clinically, including antibodies (Abs) to cytotoxic lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and the checkpoint ligand PD-L1 (Page et al., 2014) . PD-L1 is expressed mostly on steady-state antigen-presenting cells (APCs) and can be upregulated upon exposure to inflammatory signals (Keir et al., 2008) on APCs and tumor cells. Upon T cell receptor (TCR) engagement with cognate antigens, PD-L1 binds to PD-1 on T cells and modulates T cell activation by inducing TCR stop signals (Fife et al., 2009; Yokosuka et al., 2012) .
Despite significant clinical benefits, high numbers of cancer patients fail to respond to checkpoint blockade. Prior studies suggest that checkpoint inhibition might not be sufficient in patients who have limited tumor immune cell infiltration (Fuertes et al., 2011; Gajewski et al., 2013; Herbst et al., 2014; Sharma and Allison, 2015a) . However, although T cells are found accumulating in the tissue stroma surrounding the tumor mass in most human tumors, they are rarely found interacting with tumor cells (Galon et al., 2006; Salmon et al., 2012) . In a fraction of patients who resist anti-PD-L1 monoclonal Ab (mAb) therapy, CD8 + T cells localize at the edge of the tumors, whereas they accumulate in the tumor mass in patients who respond to PD-L1 blockade (Herbst et al., 2014; Tumeh et al., 2014) , suggesting that, in addition to PD-L1 inhibition, strategies aimed at promoting T cell accumulation in the tumor mass are essential for the induction of therapeutic immunity.
Through their ability to produce T-cell-specific chemokines and present antigens together with costimulatory or inhibitory (legend continued on next page) signals, tumor-associated APCs are best poised to shape antitumoral effector immunity. Most inflamed tissues harbor heterogeneous populations of APCs that comprise dendritic cells (DCs), macrophages, monocytes, and monocyte-derived cells (Merad et al., 2013) . Tissue-resident DCs consist of two functionally specialized subsets: the CD103 + -CD8 + DCs, which excel in the priming and cross-presentation of cell-associated antigens to CD8 + T cells, and CD11b + DCs, which are more potent at driving CD4 + helper T cell responses (Merad et al., 2013) . Analogous counterparts to these populations have been identified in humans and include CD141 + and CD1c + DCs, respectively (Guilliams et al., 2014) . Previous results suggest that melanoma lesions enriched in type I interferon (IFN)-induced genes are also rich in T cells and that type I IFN production by the CD103 + -CD8 + DC lineage controls spontaneous T cell priming to tumor antigens (Fuertes et al., 2011) . Thus, the composition of the tumor-associated myeloid compartment most likely plays a key role in tumor response to checkpoint blockade. In this study, we examined the composition of tumor-associated myeloid cells of two different melanoma lesions at different time points during tumor growth. We probed their contribution to the transport of tumor antigens to the tumor-draining lymph node (TdLN), to induction of anti-tumoral effector T cells, and to shaping clinical response to checkpoint inhibition. Our results revealed that increased myeloid cell commitment to the CD103 + DC lineage and activation of intratumoral CD103 + DCs could substantially enhance the clinical response to checkpoint and BRAF blockade. model in which the Braf V600E mutation, Pten deletion, and a mutated form of b-catenin that increases its stability are enforced in melanocytes upon cutaneous application of 4-hydroxytamoxifen (4-HT), leading to the formation of advanced melanoma lesions within 3 weeks (Damsky et al., 2011) .
RESULTS

CD103
In both tumor lesions, myeloid cells accounted for more than 60% of CD45 + cells and consisted mostly of monocytes and macrophages. DCs represented only a minor cell population, reaching no more than 5% of myeloid cells ( Figure 1A ). To more thoroughly evaluate the tumor-infiltrating immune populations, we used time-of-flight mass cytometry (CyTOF) and analyzed B16 tumors at two different time points. SPADE analysis revealed an accumulation of monocytes that paralleled a reduced DC to monocyte-derived cell ratio over time ( Figure 1B ). Similar data were obtained via flow cytometry ( Figure S1B ). Both CD103 + and CD11b + DC subsets were present in tumor lesions, although in very low numbers, along with macrophages and Ly6C
hi MHCII hi cells, referred to as monocyte-derived cells.
Monocyte-derived cells and macrophages expressed the monocyte markers CCR2 and CD115, the macrophage markers MertK, F4/80, and CD64, as well as detectable levels of CD11c ( Figure S1C ). To characterize DC and macrophage localization in the tumor mass, we generated fluorescent-reporter inducible melanoma lesions by crossing C57BL/6 Tyr::CreER;Braf
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loxP mice with Tomato reporter mice. We also used B16-YFP tumor cell lines in which melanoma cells are positive for the yellow fluorescent protein (YFP). Whereas macrophages and monocytederived cells were distributed throughout the tumor, DCs were sparsely distributed and rarely infiltrated the tumor mass (Figure 1C) . Consistent with these findings, human melanoma lesions were poorly infiltrated by DCs, in particular CD1c + and CD141 + DCs, in comparison to CD68 + macrophages, which accumulated throughout the tumor ( Figure 1D and S1D). These results emphasize the paucity of tumor-infiltrating DCs in mouse and human melanoma lesions.
CD103 + DCs Are the Only Intratumoral Myeloid Cell
Population that Transports Intact Antigens to the TdLNs We tracked the capture of tumor-associated fluorescent antigens by each myeloid cell compartment by using confocal microscopy and flow cytometry ( Figures 1E-1H ). Macrophages were by far the most potent cells at capturing tumor-associated fluorescence (Figures 1E and S1E) , which accumulated as puncta in intracellular compartments, consistent with antigen phagocytosis ( Figure S1F See also Figure S1 . (E and F) On day 15, mice were sacrificed, and CD8 + T cells from a TdLN (E) or tumor (F) were analyzed for the production of IFN-g and TNF-a after 3 hr stimulation with PMA and ionomycin. Shown is the mean ± SEM of two independent experiments (n = 4 or 5 mice).
(legend continued on next page) fluorescent proteins or YFPs to the TdLN, in both models (Figures 1F and 1G Figure 1H ). CD11b + migratory DCs, LN CD64 + macrophages, and monocyte-derived cells were negative for Tomato and YFP (data not shown), suggesting that they either failed to transport tumor-associated antigens or efficiently degraded the fluorescence in the TdLN. To address this question, mice were injected with B16 tumors expressing the model antigen ovalbumin (B16-OVA), and migratory and LN-resident DCs were isolated from the TdLN by fluorescence-activated cell sorting (FACS) and co-cultured with OVA-specific TCR-transgenic OT-I CD8 + T cells labeled with the cell proliferation dye, CFSE.
Migratory CD103 + DCs were the only cells able to promote
OT-I T cell activation and proliferation ( Figure 1I ). Altogether, these results demonstrate the unique ability of tumor-infiltrating CD103 + DCs to transport and cross-present tumor-associated antigens to CD8 + T cells in the TdLN, leading to the differentiation of tumor-specific CD8 + T cells. Consistent with prior results (Spranger et al., 2014) , PD-L1 blockade given alone or in combination with BRAF inhibition delayed B16 tumor growth (Figures 2B and 2C) . To investigate the contribution of CD103 + DCs to the anti-PD-L1 Ab effect, we compared B16 tumor growth upon PD-L1 blockade in wildtype (WT) or Batf3 À/À mice, which lack CD103 + -CD8 + DCs (Figure 2C) . Despite the high expression of PD-L1 on B16 tumor cells ( Figure 2D ), the moderate but significant anti-tumoral effect mediated by PD-L1 blockade was lost in Batf3 À/À mice. These results established that CD103 + DCs controlled PD-L1-mediated anti-tumor immunity.
PD-L1 Blockade Fails to Significantly Promote CD8
+ T Cell Accumulation in the Tumor Mass When combined with BRAF inhibitors, PD-L1 blockade delayed tumor growth but failed to prevent tumor relapse after interruption of BRAF inhibition ( Figure 2B ). Whereas PD-L2 expression increased on tumor migratory CD103 + DCs, its expression was strongly reduced upon BRAF inhibition ( Figure S2A ), suggesting that the poor tumor response to PD-L1 and BRAF inhibitors was not due to upregulation of PD-L2. Failure to respond to PD-L1 blockade has been shown to correlate with reduced expression of PD-L1 on tumor-infiltrating immune cells or the absence of CD8 + T cell in the tumor mass prior to treatment (Herbst et al., 2014; Tumeh et al., 2014) . Although PD-L1 inhibition increased the number of CD8 + T cells producing IFN-g and tumor-necrosis factor (TNF)-a in the TdLN ( Figure 2E ), the number of IFN-g + TNF-a + CD8 + T cells and the CD8 + T cell to regulatory T cell (Treg) ratio did not significantly increase in anti-PD-L1-treated tumors (Figures 2F and 2G) . Using tetramers, we quantified antigen presentation in the tumor and LN and observed a slight increase in the priming of tumor-specific CD8 + T cells in both sites ( Figure S2B ). However, we also found that the tumor-infiltrating T cells remained mostly outside the tumor mass, accumulating mainly within the perivascular areas in the B16 model ( Figures 2H-2J ). This suggested that defects of T cell recruitment to the tumor site might contribute to the subdued response to anti-PD-L1 Ab. These data contrast with previously published results showing increased accumulation of intratumoral CD8 + cells in Braf CA Pten loxP tumors treated with BRAF and PD-L1 blockade in comparison to BRAF blockade alone (Cooper et al., 2014) . It is plausible that the additional b-catenin mutation present in our tumor model could have contributed to the limited T cell accumulation in the tumor. This would be consistent with recently published data showing that b-catenin expression in melanoma lesions alters chemokine production, thereby compromising DC and T cell recruitment (Spranger et al., 2015) .
FLT3L Injections Dramatically Expand CD103 + DC Progenitors in the Bone Marrow and Promote Their Accumulation and Proliferation in the Tumor Mass
We hypothesized that the paucity of CD103 + DCs at the tumor site restricted the expansion of tumor-specific CD8 + T cells and therefore limited anti-PD-L1 Ab anti-tumor efficacy. Another possibility was that the excess of highly phagocytic macrophages competed for antigen availability at the tumor site thereby limiting the ability of CD103 + DCs to prime and activate CD8 + T cells.
To expand CD103 + DCs, we injected mice with the growth factor FMS-like tyrosine kinase 3 ligand (FLT3L, referred to hereafter as FL), a cytokine promoting hematopoietic progenitor commitment to the DC lineage as well as DC survival and proliferation in tissues (Liu and Nussenzweig, 2010) . We found that nine daily injections of FL dramatically expanded CD103 + DCs, which became the predominant myeloid cell population at the tumor (G) CD8 + T cell to Treg cell ratio 15 days after tumor challenge is shown as the mean ± SEM of two independent experiments (n = 4 or 5).
(H) B16-YFP tumors were harvested on day 13 (2 days after the last injection of anti-PD-L1 or control mAb) and stained with anti-CD3 mAb. The density of CD3 Figure 3D ), a transcription factor required for the differentiation of CD103 + DCs but not CD11b + DCs (Ginhoux et al., 2009 ) and lacked IRF4, the transcription factor required for the differentiation of CD11b + DCs (Murphy et al., 2013 ) ( Figure 3D ). IRF8 + DN cells proliferated actively in the tumor ( Figure 3G ), suggesting that FL injections led to the expansion of DC progenitors committed to the CD103 + DC lineage and their accumulation at the tumor site. To directly address whether IRF8 + DN cells gave rise to CD103 + DCs, we sorted the DN cells from B16 tumors of FL-treated mice and cultured them in vitro in the presence of FL ± granulocyte-macrophage colony-stimulating factor (GM-CSF) as previously described (Sathe et al., 2011; Schlitzer et al., 2015) ( Figure S3A (Bogunovic et al., 2011; Bogunovic et al., 2009; Longhi et al., 2009; Matsumoto and Seya, 2008) . Production of type I IFN by the CD103 + -CD8 + DC lineage is required for T cell priming against tumor antigens Fuertes et al., 2011) . Thus, we chose intratumoral pIC delivery to activate CD103 + DCs, increase type I IFN availability at the tumor site, and limit potential immune adverse events due to CD103 + DC activation in other tissues ( Figure S4A ).
pIC injections upregulated the expression levels of the costimulatory molecules CD40, CD86, and MHCII on tumor-infiltrating CD103 + DCs ( Figure 4A ) and to a lesser extent on CD11b + DCs (data not shown), indicating proper DC maturation and activation. The significant increase of DC progenitor and mature DC numbers in the tumor mass was accompanied by a significant increase of OVA-specific IFN-g + CD8 + OT-I cell frequencies in the TdLNs of mice injected with B16-OVA tumors and with OT-I cells, in comparison to control groups ( Figure 4B ). Combined FL-pIC also led to the expansion of CD8 + T cells specific to the melanocyte antigen gp100 in the TdLNs of B16-tumor-bearing mice ( Figure 4C ), suggesting that the combined therapy could also promote the priming and/or expansion of T cells specific for endogenous tumor-associated antigens. Although, in comparison to PBS injections, pIC injections led to reduced B16 tumor lesions, FL-pIC significantly enhanced tumor regression in comparison to tumors treated with PBS, FL alone, or pIC alone ( Figure 4D) . Similar to what we observed with B16 tumors, FL-pIC treatment also significantly reduced Braf-mutant tumor growth in comparison to the PBS-and FL-treated groups ( Figure 4E ). Although not statistically significant, there was a clear trend toward a superior clinical effect in the FL-pIC-treated group compared to the pIC-treated mice.
We compared the anti-tumor effect of systemic versus intratumoral injections of pIC and observed, in a dose-equivalent manner, a much stronger anti-tumor effect when pIC was administered intratumorally ( Figure 4F ). Thus, intratumoral injections helped lower the pIC dose and reduce its potential toxicity.
Because a majority of patients who initially respond to BRAF blockade do relapse (Flaherty et al., 2010) , we investigated whether FL-pIC combined treatment increases anti-tumor immunity to melanoma antigens released upon BRAF inhibition therapy and therefore prolongs tumor response to BRAF blockade in mice bearing Braf-mutant melanoma lesions (Figure S4B) . Similarly to what was observed in B16-tumor-bearing mice, FL-pIC combined therapy enhanced the proliferation of gp100-specific T cells in the TdLN ( Figure 4G ) and significantly (C) B16-tumor-bearing mice were treated with FL and pIC as in (A) and adoptively transferred with violet-labeled gp100-specific T cells. TdLNs were harvested 4 days after i.v. injection of gp100-specific T cells, and their proliferation was assessed based on violet dilution via flow cytometry. Shown is a representative histogram of two independent experiments. (D) B16-tumor-bearing mice were treated with FL, pIC, FL-pIC, or PBS as shown in (A). Graph shows the mean tumor growth ± SEM of four independent experiments (n = 7-12).
(E) Braf-mutant tumor-bearing mice were treated as in (A), with FL injections starting on day 15 after 4-HT application. Graphs show the mean tumor growth ± SEM of two independent experiments (n = 5).
(F) B16-tumor-bearing mice were treated with PBS (control) or pIC (50 mg or 200 mg) intratumorally or i.p. as in (A) (injections on days 7 and 11). Graph shows the mean tumor growth ± SEM of two independent experiments (n = 3-6 mice).
(G) Braf-mutant-tumor-bearing mice were treated as described in Figure S4B . On day 26, 2 hr after the last injection of FL-pIC or PBS, mice were adoptively transferred with violet-labeled gp100-specific T cells. TdLNs were harvested 4 days after gp100-specific T cell transferred cells and proliferation was assessed through Violet-Cell trace dilution. Shown is a representative histogram of two independent experiments. (H) Braf-mutant-tumor-bearing mice were treated as described in Figure S4B . Graph shows the mean tumor growth ± SEM of two independent experiments (n = 5 or 6 mice). See also Figure S4 .
reduced tumor relapse after interruption of BRAF inhibitors in comparison to the control group ( Figure 4H ).
Therapeutic Immunity Induced by FL-pIC Combined Treatment Requires CD103 + DCs and type I IFN
Although a slight T cell accumulation was induced upon BRAF inhibition alone, BRAF inhibition combined with FL-pIC treatment promoted a massive T cell infiltration throughout the tumor ( Figures 5A and 5B) . Accordingly, whereas T lymphocytes were almost absent in untreated B16 tumors, FL-pIC increased T cell frequency per mm in the tumor and promoted T cell proliferation in situ ( Figures 5C-5E ). FL-pIC treatment significantly increased the number of tumor-infiltrating antigen-specific cytolytic and IFN-g + TNF-a + CD8 + T cells (Figures 5F and 5G and S4C) and increased CD8 + T cell to Treg cell ratio at the tumor site ( Figure 5H ). Upon injections of the sphingosine 1 phosphate (S1P) receptor antagonist FTY-720, we found a drastic reduction in OT-I cell numbers in the tumors of FL-pIC-treated mice ( Figures 5I and  S5C ). FTY-720 is known to prevent T cell egress from the LN (Figure S5D) ; therefore, these results could suggest that T cell priming in the TdLN is required to promote the FL-pIC anti-tumor response. Additional experiments will be required to further characterize the contribution of the TdLN versus the tumor site to the induction of anti-tumor immunity.
We then asked whether CD103 + DCs controlled the FL-pICmediated anti-tumor effect. B16 tumors injected in Batf3 -/-animals, which lack CD103 + and CD8 + DCs, did not respond to FL-pIC combined therapy ( Figure 5J ). Accordingly, effector T cells failed to accumulate in FL-pIC-treated tumors in Batf3 -/-animals in comparison to WT animals ( Figure 5K ).
These results strongly suggest that induction of anti-tumoral effector immunity in FL-pIC-treated mice is dependent on CD103 + DCs.
Depletion of natural killer (NK) cells in FL-pIC-treated mice did not compromise tumor outcome ( Figure 5L ), indicating that NK cells were dispensable for the FL-pIC-mediated anti-tumor effect. In contrast, depletion of CD4 + and CD8 + T cells prior to FL-pIC injection reduced the FL-pIC therapeutic effect without totally abrogating it ( Figure 5L ), suggesting that the regression of primary tumors was partially dependent on T cell responses but also on innate immunity induced by CD103 + DCs. We found that B16 tumors injected into mice lacking the IFN alpha receptor (Ifnar À/À ) failed to respond to FL-pIC therapy (Figure S5A) , which was consistent with prior studies showing that type I IFN signature at the tumor site correlates with anti-tumoral immunity (Fuertes et al., 2011) . We found that, similarly to what occurred in Ifnar À/À mice, B16 tumors injected into Ifnar -/-bone marrow chimeric animals did not respond to FL-pIC treatment ( Figure S5B ). pIC acts through two RNA sensors, TLR3 and melanoma differentiated antigen 5 (MDA5) (Kawai and Akira, 2010) . TLR3, which is highly expressed on CD103 + DCs but is lacking on other APCs , uses TRIF for the induction of type I IFN (Kawai and Akira, 2010) . We reconstituted mice with bone marrow cells lacking TRIF so that immune cells were unable to respond to TLR3 signaling but should still be able to respond to MDA5. We found that the absence of TLR3-TRIF in immune cells greatly compromised the B16 tumor response to FL-pIC treatment ( Figure S5B ). Altogether, these data suggest that CD103 + DCs, as well as IFN alpha receptor and TRIF expression in the immune compartment, controlled the FL-pIC anti-tumoral effect.
FL and pIC Synergize with anti-PD-L1 Ab Treatment to Enhance Anti-tumor Responses to BRAF Inhibition
In accordance with previous studies, we found that in situ pIC injections substantially increased the expression of PD-L1 on intratumoral CD103 + DCs ( Figure 6A ), suggesting that PD-L1 upregulation on APCs might limit the therapeutic efficacy of FL-pIC therapy. Thus, we compared the clinical outcome of mice treated with the combined FL-pIC and anti-PD-L1 Ab therapy (referred to as ''tritherapy'') to mice treated with FL-pIC or anti-PD-L1 Ab alone. The tritherapy dramatically increased the regression of B16 established tumors ( Figure 6B ). Accordingly, PD-L1 inhibition combined with FL-pIC further increased the number of IFN-g + TNF-a + CD8 + T cells in B16 TdLNs and tumors and increased the CD8 + T cell to Treg cell ratio in tumors in comparison to mice treated with FL-pIC or anti-PD-L1 Ab alone ( Figures  6C-6E ). Treg cells' absolute numbers were not decreased, but their frequency was reduced due to increased recruitment and proliferation of CD8 + T effector cells (data not shown).
The improved clinical outcome of B16 tumors treated with the tritherapy prompted us to test whether it could be used to further reduce the relapse of Braf-mutant lesions after interruption of BRAF inhibition. Whereas tumor growth was delayed but not abrogated in control groups treated with anti-PD-L1 Ab or FL-pIC alone, Braf-mutant lesions treated with the tritherapy were strongly reduced upon interruption of BRAF blockade ( Figure 6F ).
We then probed the tritherapy effect on secondary tumors that developed upon tumor rechallenge induced through 4-HT readministration. Given that the secondary tumors did not receive any treatment, their regression should depend on a memory antitumor immune response induced upon treatment of the primary tumors. Thus, mice harboring Braf-mutant tumors were treated with the tritherapy, anti-PD-L1 Ab alone, or immunoglobulin G (IgG)-PBS, in addition to BRAF inhibition, as in Figure 6F . Ten days after treatment interruption, mice were rechallenged with 4-HT on the opposite flank of the treated primary tumors and analyzed one month later ( Figure S6A ). Compared to mice initially treated with anti-PD-L1 alone or with isotype control, mice in which the primary tumors were treated with the tritherapy developed much smaller secondary tumors accompanied with increased accumulation of IFN-g + TNF-a + CD8 + T cells in the TdLN along with massive T cell accumulation in the tumors ( Figures 6G-6J ). PD-L1 inhibition alone did not confer superior protective immunity compared to that of non-treated animals ( Figures 6G-6J transgenic mice develop serial skin tumors on ears, eyes, paws, and tail within 2 months after primary tumor induction with 4-HT. These secondary tumors could represent either skin metastases or tumors that form due to leakiness of the cre-transgene. Consistent with our findings upon tumor rechallenge, mice in which the primary tumors were treated with the tritherapy in addition to BRAF inhibition had significantly reduced skin tumors ( Figure 6K ) in (B) CD3 + T cell density was quantified from confocal images with Cell Profiler software. Shown is the mean ± SEM of two independent experiments (n = 3 or 4;
12-16 tiled 203 images were analyzed per animal).
(legend continued on next page)
comparison to mice treated with anti-PD-L1 Ab combined with BRAF inhibitors. This was dependent on T cell immunity given that T cell depletion abrogated the clinical benefit of tritherapy on the development of secondary tumors ( Figures 6I and 6K) . Altogether, these data show that FL and pIC synergized with PD-L1 blockade to prevent the relapse of Braf-mutant melanoma lesions after BRAF inhibition and to protect from tumor rechallenge.
Discussion
In the present study we found that, although most tumor-infiltrating myeloid cells could capture tumor antigens in two mouse melanoma models, tumor-infiltrating CD103 + DCs were uniquely able to transport intact antigens to the TdLN and prime tumorspecific LN CD8 + T cells. CD103 + DCs controlled anti-PD-L1-Ab-mediated anti-tumor immunity; however, PD-L1 inhibition led to modest anti-tumor response, and this response was dramatically increased upon expansion and activation of CD103 + DC at the tumor site.
Our findings that intratumoral CD103 + DCs are uniquely able to transport intact antigens to the TdLN are consistent with the low expression levels of lysosomal degradative enzymes Savina et al., 2006) and in line with our previous results showing that lung-resident CD103 + DCs are uniquely able to transport intact viral antigens to the LN upon lung infection with influenza virus . These results are also in accordance with prior studies showing the requirement for CD103 + DCs in the induction of therapeutic immunity against fibrosarcoma tumor grafts (Hildner et al., 2008) . The low numbers of CD8 + T cells present in B16 and Brafmutant tumors and their limited accumulation upon BRAF and/ or PD-L1 blockade might explain the reduced clinical response to these treatments, as previously suggested (Chen and Mellman, 2013; Gajewski et al., 2013) . Using an experimental model of breast cancer, recent results revealed that accumulation and activation of intratumoral CD8 + T effector cells is dependent on intratumoral CD103 + DCs (Broz et al., 2014) (Liu and Nussenzweig, 2010; Miller et al., 2012) and suggests that increased Flt3 signaling might enforce IRF8 signaling, thereby promoting CD103 + DC differentiation.
The expansion of CD103 + DC progenitors was associated with a substantial accumulation at the tumor site of immature (G) CD8 + T cells were analyzed for IFN-g and TNF-a production after PMA and ionomycin stimulation. Shown is the mean ± SEM of four independent experiments (n = 8).
(H) Tumor-infiltrating CD8 + T cell to Treg cell ratio as the mean ± SEM of four independent experiments (n = 8).
(I) Mice bearing B16-OVA tumors received daily FL injections from day 5 to 9 after tumor challenge; this was followed by one intratumoral injection of pIC at day 9. Two hours after the pIC injection, tumor-bearing mice were injected with 3 3 10 6 naive tumor antigen-specific CD8 + T cells (OT-I) in the presence or absence of the S1P receptor antagonist FTY-720 (from day 9, daily injection as described in the Experimental Procedures). Shown are representative dot plots (left) and quantification of the frequency and absolute numbers of tumor-infiltrating OT-I cells (right) four days after adoptive cell transfer. Graphs show the mean ± SEM of two independent experiments (n = 4 or 5). (L) B16-tumor-bearing mice treated with FL-pIC and with anti-CD4, anti-CD8, or anti-NK1.1 Ab or control IgG as described in the Experimental Procedures. Graph shows the mean tumor growth ± SEM of two independent experiments (n = 3-9). See also Figure S5 .
The presence of the human CD103 + DC equivalent, CD141 + DCs, correlates with better outcome in human tumors (Sluijter et al., 2015) . Similarly to mouse CD103 + DCs, human CD141 + DCs express IRF8 and high levels of FLT3 and TLR3, and pIC activation of human CD141 + cells leads to the upregulation of PD-L1 (Bogunovic et al., 2011) and to their increased cross-priming of CD8 + T cells (Crozat et al., 2010; Jongbloed et al., 2010; Poulin et al., 2010) . This suggests that FL-pICanti-PD-L1 Ab tritherapy should help expand and activate tumor-infiltrating DCs and promote the induction of tumor-specific CD8 + T cell immunity in cancer patients.
Compared to monotherapic regimens, the introduction of combination chemotherapy in the 1960s dramatically improved the clinical outcome of numerous tumors (Frei et al., 1958) . Our results support the need of novel immunotherapy combination strategies to maximize the induction, expansion, recruitment, and cytotoxic function of tumor-specific CD8 + T cells. We believe that the use of FL to expand CD103 + DC progenitors at the tumor site, followed by intratumoral pIC to induce type I IFN release in the tumor and promote DC immunogenic function, has the potential to transform clinical response to anti-PD-L1 treatment in cancer patients. Figure S6A , and the number of skin tumors was assessed a month after the end of treatment. Bar graph shows the mean number of skin tumors ± SEM of two independent experiments (n = 5 or 6). See also Figure S6 . 
EXPERIMENTAL PROCEDURES
Tumor Induction
The C57BL/6-derived melanoma cell line B16 (Mayordomo et al., 1995) , the B16-OVA-transfected clone, and the B16YFP-transfected clone were maintained at 37 C with 5% CO 2 in RPMI medium supplemented with 10% heat-inactivated fetal calf serum, penicillin, and streptomycin (Cellgro). 3 3 10 5 tumor cells were injected subcutaneously in 50 ml PBS on the flank. Braf-mutant melanoma lesions were induced by topical application of 1 ml of 5 mM 4-hydroxytamoxifen. Tumor size was determined by the formula L 3 W 3 D where L = length, W = width, and D = depth, on the indicated days.
Treatments FL (30 mg in 100 ml PBS; Celldex) or control PBS was injected intraperitoneally (i.p.; nine daily injections, unless otherwise noted). High molecular weight pIC (50 mg in 50 ml; InvivoGen) was injected intratumorally. For BRAF inhibition, mice were either fed a chow diet containing 417 mg/kg PLX4720 (Plexxikon) for 4 days or a control diet.
Preparation of Cell Suspensions
Single cell suspension was obtained after tumor digestion with 400 U/ml of type D collagenase (Roche) at 37 C for 1 hr. Hematopoietic cells were enriched by density gradient centrifugation with 40/90 Percoll (GE Healthcare Life Sciences) for 30 min at 2,500 rpm before a 1 min incubation with red blood cell (RBC) lysis buffer (BioLegend) at room temperature. DCs were obtained from LNs after incubation with 400 U/ml Collagenase D (Roche) for 25 min at 37 C. In some cases, DC enrichment was performed with CD11c microbeads according to the manufacturer's instructions (Miltenyi Biotec).
FTY-720 Treatment FTY-720 was purchased from Sigma, and injected i.p. (200 ml) at a final concentration of 100 mg/ml in saline every day over the indicated time periods.
Re-stimulation and Intracellular Cytokine Staining Cells were stimulated with 100 ng/ml PMA (Sigma) and 0.5 mg/ml ionomycin (Sigma-Aldrich) at 37 C for 3 hr in the presence of Brefeldin A (10 mg/ml; Sigma)
to allow accumulation of intracellular cytokines. After staining of surface markers, cells were fixed and permeabilized, followed by staining of IFN-g, TNF-a, and Foxp3.
